##gff-version 3
##sequence-region Q9H4E5 1 214
Q9H4E5	UniProtKB	Chain	1	211	.	.	.	ID=PRO_0000198869;Note=Rho-related GTP-binding protein RhoJ	
Q9H4E5	UniProtKB	Propeptide	212	214	.	.	.	ID=PRO_0000281220;Note=Removed in mature form;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q9H4E5	UniProtKB	Nucleotide binding	31	36	.	.	.	Note=GTP;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q92730	
Q9H4E5	UniProtKB	Nucleotide binding	46	53	.	.	.	Note=GTP;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q92730	
Q9H4E5	UniProtKB	Nucleotide binding	75	79	.	.	.	Note=GTP;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q92730	
Q9H4E5	UniProtKB	Nucleotide binding	133	136	.	.	.	Note=GTP;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q92730	
Q9H4E5	UniProtKB	Nucleotide binding	177	178	.	.	.	Note=GTP;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q92730	
Q9H4E5	UniProtKB	Motif	50	58	.	.	.	Note=Effector region;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q9H4E5	UniProtKB	Modified residue	211	211	.	.	.	Note=Cysteine methyl ester;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:P62745	
Q9H4E5	UniProtKB	Lipidation	3	3	.	.	.	Note=S-palmitoyl cysteine;Ontology_term=ECO:0000305;evidence=ECO:0000305|PubMed:30158707;Dbxref=PMID:30158707	
Q9H4E5	UniProtKB	Lipidation	11	11	.	.	.	Note=S-palmitoyl cysteine;Ontology_term=ECO:0000305;evidence=ECO:0000305|PubMed:30158707;Dbxref=PMID:30158707	
Q9H4E5	UniProtKB	Lipidation	211	211	.	.	.	Note=S-farnesyl cysteine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:P62745	
Q9H4E5	UniProtKB	Alternative sequence	113	134	.	.	.	ID=VSP_007231;Note=In isoform 2. Missing;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:14702039;Dbxref=PMID:14702039	
Q9H4E5	UniProtKB	Mutagenesis	3	3	.	.	.	Note=Impaired localization to the plasma membrane. C->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:30158707;Dbxref=PMID:30158707	
Q9H4E5	UniProtKB	Mutagenesis	11	11	.	.	.	Note=Impaired localization to the plasma membrane. C->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:30158707;Dbxref=PMID:30158707	
Q9H4E5	UniProtKB	Mutagenesis	17	20	.	.	.	Note=Impaired localization to the plasma membrane. DEKK->AAAA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27660391;Dbxref=PMID:27660391	
Q9H4E5	UniProtKB	Mutagenesis	17	18	.	.	.	Note=Does not affect localization to the plasma membrane. DE->AA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27660391;Dbxref=PMID:27660391	
Q9H4E5	UniProtKB	Mutagenesis	19	20	.	.	.	Note=Impaired localization to the plasma membrane. KK->AA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27660391;Dbxref=PMID:27660391	
Q9H4E5	UniProtKB	Mutagenesis	30	30	.	.	.	Note=Causes constitutive activation. G->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27660391;Dbxref=PMID:27660391	
Q9H4E5	UniProtKB	Mutagenesis	35	35	.	.	.	Note=Dominant negative mutant. T->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27660391;Dbxref=PMID:27660391	
Q9H4E5	UniProtKB	Mutagenesis	79	79	.	.	.	Note=Causes constitutive activation. Q->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27660391;Dbxref=PMID:27660391	
Q9H4E5	UniProtKB	Sequence conflict	3	3	.	.	.	Note=C->R;Ontology_term=ECO:0000305;evidence=ECO:0000305	
